Research leader, professor, ph.d. Per Damkier Pharmacology, Odense University Hospital
Projektet i tal
OPEN undersøgelse/kliniske data
Forventet # af deltagere
Inkluderet antal deltagere
Forventede deltagere med prøver
Inkluderede deltagere med prøver
Neurofilament light chain as biomarker for bortezomib-induced peripheral neuropathy
Chemotherapy-induced peripheral neuropathy is an adverse side effect to commonly used chemotherapy. Newer research within the field have studied, neurofilament light chain as a biomarker for chemotherapy-induced peripheral neuropathy and have found promising results. We want to investigate if neurofilament light chain can be used as biomarker for bortezomib-induced peripheral neuropathy.
The aim of the project is to investigate whether a blood sample can be used to predict which patients have increased risk of developing peripheral neuropathy when treated with bortezomib.
Description of the cohort
Paticipants are patients with multiple myeloma included at Odense University Hospital and Aarhus University Hospital. They must be 18 years of age or above, and candidates for treatment with bortezomib. They can not be candidates for staem cell
Data and biological material
Categoric data is collected: demografic, type of diagnose, data from the patient journal and questionnaire data. Blood samples are collected for measurement of plasma level of neurofilament light chain.
Collaborating researchers and departments
Department of Blood Diseases, Aarhus University Hospital
Mette Kathrine Nygaard
Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark
Tore Bjerregaard Stage
Department of Haematology X, Odense University Hospital
Ida Bruun Kristensen
Department of Immunology and Biochemistry, Lillebaelt Hospital, Vejle